Translated NewsAs the global pharmaceutical market evolves, the EU is losing ground in cutting-edge areas such as biologics and orphan medicines, not to mention new therapies. The reasons for this loss of competitiveness are similar to those that Draghi identifies in other sectors: fragmented and insufficient public investment in R&D, little support for private investment and an overly complex regulatory framework
